REAL-WORLD OUTCOMES OF NOVEL TREATMENTS IN PATIENTS WITH ADVANCED CUTANEOUS MELANOMA IN THE NETHERLANDS

Author(s)

Leeneman B¹, Franken M¹, Jochems A², Schouwenburg M³, Aarts M⁴, van Akkooi A⁵, van den Berkmortel F⁶, van den Eertwegh A⁷, Groenewegen G⁸, de Groot J⁹, Haanen J⁵, Hospers G¹⁰, Kapiteijn E², Koornstra R¹¹, Kruit W¹², Louwman M¹³, Piersma D¹⁴, van Rijn R¹⁵, ten Tije A¹⁶, Vreugdenhil G¹⁷, Wouters M⁵, van Zeijl M³, van der Hoeven J¹¹, Uyl - de Groot C¹
¹Erasmus University Rotterdam, Rotterdam, The Netherlands, ²Leiden University Medical Center, Leiden, The Netherlands, ³Dutch Institute for Clinical Auditing, Leiden, The Netherlands, ⁴Maastricht University Medical Center, Maastricht, The Netherlands, ⁵Netherlands Cancer Institute, Amsterdam, The Netherlands, ⁶Zuyderland, Heerlen, The Netherlands, ⁷VU University Medical Center, Amsterdam, The Netherlands, ⁸University Medical Center Utrecht, Utrecht, The Netherlands, ⁹Isala, Zwolle, The Netherlands, ¹⁰University Medical Center Groningen, Groningen, The Netherlands, ¹¹Radboud University Medical Center, Nijmegen, The Netherlands, ¹²Erasmus Medical Center, Rotterdam, The Netherlands, ¹³Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, ¹⁴Medical Spectrum Twente, Enschede, The Netherlands, ¹⁵Medical Center Leeuwarden, Leeuwarden, The Netherlands, ¹⁶Amphia, Breda, The Netherlands, ¹⁷Maxima Medical Center, Eindhoven, The Netherlands

OBJECTIVES: Novel treatments improved survival in patients with advanced cutaneous melanoma in clinical trials. We assessed real-world outcomes of novel treatments in The Netherlands. METHODS: Data were retrieved from the Dutch Melanoma Treatment Registry (DMTR) for patients diagnosed with advanced cutaneous melanoma between July 2012 and April 2016 (data cut-off March 20, 2016). The DMTR prospectively records detailed data on all Dutch unresectable stage IIIc/IV melanoma patients. Descriptive statistics and Kaplan-Meier estimates were used to assess real-world outcomes. RESULTS: A total of CONCLUSIONS: Novel treatments improved survival in patients with advanced cutaneous melanoma in Dutch real-world practice. Patients with elevated LDH, M1c disease and brain metastases had worse survival outcomes. Of all patients with severe adverse events, 50% early discontinued treatment but only one treatment-related death occurred.

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PCN8

Topic

Clinical Outcomes, Epidemiology & Public Health

Topic Subcategory

Comparative Effectiveness or Efficacy, Relating Intermediate to Long-term Outcomes, Safety & Pharmacoepidemiology

Disease

Oncology

Explore Related HEOR by Topic

Presentation